ALNYLAM PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2010 to Q3 2024.
  • Alnylam Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$112M, a 176% decline year-over-year.
  • Alnylam Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$332M, a 34.8% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$440M, a 61.1% increase from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$1.13B, a 32.6% decline from 2021.
  • Alnylam Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$853M, a 0.64% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$332M -$112M -$259M -176% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 -$72.9M -$16.9M +$259M +93.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-10-31
Q1 2024 -$332M -$65.9M +$108M +62.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-10-31
Q4 2023 -$440M -$138M +$69.6M +33.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 -$510M $148M +$554M Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 -$1.06B -$276M +$1.38M +0.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-31
Q1 2023 -$1.06B -$174M +$66.2M +27.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-10-31
Q4 2022 -$1.13B -$207M +$51M +19.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 -$1.18B -$406M -$201M -98.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$981M -$277M -$87.8M -46.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-02
Q1 2022 -$893M -$240M -$40.1M -20% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-02
Q4 2021 -$853M -$258M -$14.9M -6.13% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 -$838M -$205M +$48.8M +19.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 -$887M -$190M -$10.3M -5.76% Apr 1, 2021 Jun 30, 2021 10-Q 2022-10-27
Q1 2021 -$876M -$200M -$18.1M -9.92% Jan 1, 2021 Mar 31, 2021 10-Q 2022-10-27
Q4 2020 -$858M -$244M +$32.6M +11.8% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-11
Q3 2020 -$891M -$253M -$44.8M -21.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 -$846M -$179M +$40.3M +18.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-10-28
Q1 2020 -$886M -$182M -$306K -0.17% Jan 1, 2020 Mar 31, 2020 10-Q 2021-10-28
Q4 2019 -$886M -$276M -$64.7M -30.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-11
Q3 2019 -$821M -$209M +$36.7M +15% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-11
Q2 2019 -$858M -$219M -$55.9M -34.2% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-11
Q1 2019 -$802M -$182M -$40.7M -28.8% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-11
Q4 2018 -$761M -$211M -$69.2M -48.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-13
Q3 2018 -$692M -$245M -$122M -99.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-13
Q2 2018 -$570M -$164M -$45.1M -38.1% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-13
Q1 2018 -$525M -$141M -$33.9M -31.6% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-13
Q4 2017 -$491M -$142M -$29.3M -25.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-14
Q3 2017 -$462M -$123M -$18.9M -18.1% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-14
Q2 2017 -$443M -$118M -$28.3M -31.4% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-14
Q1 2017 -$414M -$107M -$4.32M -4.19% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-14
Q4 2016 -$410M -$113M -$22.2M -24.5% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-15
Q3 2016 -$388M -$104M -$27.3M -35.5% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-15
Q2 2016 -$361M -$90.1M -$18.3M -25.6% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-15
Q1 2016 -$342M -$103M -$52.2M -103% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-15
Q4 2015 -$290M -$90.7M -$69.3M -324% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-15
Q3 2015 -$221M -$76.8M -$32.8M -74.6% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-15
Q2 2015 -$188M -$71.8M -$27.7M -62.9% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-15
Q1 2015 -$160M -$50.8M +$200M +79.8% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-15
Q4 2014 -$360M -$21.4M +$11M +33.9% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-12
Q3 2014 -$371M -$44M -$14.3M -48.2% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-12
Q2 2014 -$357M -$44.1M -$25.9M -143% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-12
Q1 2014 -$331M -$251M -$242M -2684% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-12
Q4 2013 -$89.2M -$32.4M +$29.8M +48% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-13
Q3 2013 -$119M -$29.7M -$10.2M -52.2% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-13
Q2 2013 -$109M -$18.2M -$5.21M -40.2% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-13
Q1 2013 -$104M -$9.01M +$2.36M +20.7% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-13
Q4 2012 -$106M -$62.2M -$47.9M -335% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-20
Q3 2012 -$58.1M -$19.5M -$6.27M -47.3% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-20
Q2 2012 -$51.9M -$13M +$868K +6.28% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-20
Q1 2012 -$52.7M -$11.4M +$4.92M +30.2% Jan 1, 2012 Mar 31, 2012 10-K 2014-02-20
Q4 2011 -$57.6M -$14.3M -$7.37M -106% Oct 1, 2011 Dec 31, 2011 10-K 2013-02-19
Q3 2011 -$50.3M -$13.2M -$3.61M -37.5% Jul 1, 2011 Sep 30, 2011 10-K 2013-02-19
Q2 2011 -$46.7M -$13.8M +$808K +5.52% Apr 1, 2011 Jun 30, 2011 10-K 2013-02-19
Q1 2011 -$47.5M -$16.3M -$3.96M -32.2% Jan 1, 2011 Mar 31, 2011 10-K 2013-02-19
Q4 2010 -$43.5M -$6.93M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-19
Q3 2010 -$9.63M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-03
Q2 2010 -$14.6M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-03
Q1 2010 -$12.3M Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.